Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas

Cytokine

Volumn 57, Issue 3, 2012, Pages 347-359

  Revoltella, Roberto P ^a   Menicagli, Michele ^b   Campani, Daniela ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Glioblastoma multiforme; GM CSF; GM CSF receptor; Human glioma; Tumor progression

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NERVE GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOCRINE EFFECT; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL ADHESION; CELL CLONE; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR GENE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BLOCKING; APOPTOSIS; AUTOCRINE COMMUNICATION; BIOLOGICAL ASSAY; BLOTTING, NORTHERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; CULTURE MEDIA; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, BIOLOGICAL; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84856399697     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.016     Document Type: Article

References (73)

1. Wong G.G., Witek J.S., Temple P.A., et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985, 228:810-815.
2. Lopez A.F., Williamson D.J., Gamble J.R., et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986, 78:1220-1228.
3. Metcalf D., Nicola N.A. Biological actions of the colony-stimulating factors in vitro, in: The Hematopoietic Colony-Stimulating Factors 1995, Cambridge University Press, Cambridge, UK.
4. Metcalf D., Nicola N.A. Clinical use of the colony-stimulating factors. The Hematopoietic Colony-Stimulating Factors 1995, Cambridge University Press, Cambridge, UK.
5. Gasson J.C., Kaufman S.E., Weisbart R.H., Tomonaga M., Golde D.W. High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci USA 1986, 83:669-673.
6. Gearing D.P., King J.A., Gough N.M., Nicola N.A. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J 1989, 8:3667-3676.
7. Hayashida K., Kitamura T., Gorman D.M., Arai K., Yokota T., Miyajima A. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990, 87:9655-9659.
8. Cannistra S.A., Koenigsmann M., DiCarlo J., Groshek P., Griffin J.D. Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem 1990, 265:12656-12663.
9. Isfort R.J., Ihle J.N. Multiple hematopoietic growth factors signal through tyrosine phosphorylation. Growth Factors 1990, 2:213-220.
10. Kanakura Y., Druker B., Cannistra S.A., Furukawa Y., Torimoto Y., Griffin J.D. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood 1990, 76:706-715.
11. Okuda K., Sanghera J.S., Pelech S.L., Kanakura Y., Hallek M., Griffin J.D., et al. Granulocyte-macrophage colony-stimulating factor and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood 1992, 79:2880-2887.
12. Kastelein R.A., Shanafelt A.B. GM-CSF receptor: interactions and activation. Oncogene 1993, 8:231-236.
13. American Society of Clinical Oncology American Society of Clinical Oncology: recommendations for the use of the hematopoietic colony stimulating factors: evidence based clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508.
14. Dedhar S., Gaboury L., Galloway P., Eaves C. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci USA 1988, 85:9253-9257.
15. Modrowski D., Lomri A., Mariel P.J. Endogenous GM-CSF is involved as an autocrine growth factor for human osteoblastic cells. J Cell Physiol 1997, 170:35-46.
16. Hamilton J.A., Piccoli D.S., Cebon J., et al. Blood 1992, 79:1413-1419.
17. Bussolino F., Wang J.M., Defilippi P., Turrini F., Sanavio F., Edgel C.J., et al. Nature 1989, 337:471-473.
18. Inaba K., Steinman R.M., Pack M.W., Aya H., Inaba M., Sudo T., et al. J Exp Med 1992, 175:1157-1167.
19. Stoof T.J., Boorsma D.M., Nickoloff B.J. Keratinocytes and immunological cytokines. Cambridge 1994, 363-399. University Press. I., F. Watt (Eds.).
20. Breuhahn K., Mann A., Muller G., et al. Epidermal overexpression of granulocyte-macrophage colony-stimulating factor induces both keratinocyte proliferation and apoptosis. Cell Growth Differ 2000, 11:111-121.
21. Wegmann T.G., Athanassakis I., Guilbert L., et al. The role of M-CSF and GM-CSF in fastening placental growth, fetal growth, and fetal survival. Transplant Proc 1989, 21:566-571.
22. Harris R.J., Pettitt A.R., Schmutz G., et al. Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature and malignant B-lymphocyte. J Immunol 2000, 164:3887-3893.
23. Lang S.H., Miller W.R., Duncan W., Habib F.K. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. Int J Cancer 1994, 59:235-241.
24. Tachibana M., Miyakawa A., Tazaki H., et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1995, 55:3438-3443.
25. Baldwin G.C., Golde D.W., Widhopf G.F., Economou J., Gasson J.C. Identification and characterization of a low-affinity granulocyte-macrophage colony-stimulating factor receptor on primary and cultured human melanoma cells. Blood 1991, 78:609-615.
26. Baldwin G.C., Gasson J.C., Kaufman S.E., et al. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 1989, 73:1033-1037.
27. Baldwin G.C. The biology of granulocyte-macrophage colony stimulating factor: effects on hematopoietic and non-hematopoietic cells. Dev Biol 1992, 151:352-367.
28. Mueller M.M., Fusenig N.E. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer 1999, 83:780-789.
29. Miyagawa K., Chiba S., Shibuya K., et al. Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines. J Cell Physiol 1990, 143:483-487.
30. Kleihues P., Burger P.C., Scheithauer B.W. The new WHO classification of brain tumors. Brain Pathol 1993, 3:255-268.
31. Salcman M. High-grade glioma. Handbook of Clinical Neurology. Neuro-oncology, vol. 24 1997, 95-97. Amsterdam Elsevier. J. Vecht (Ed.).
32. Frei K., Piani D., Malipiero U.V., Van Meir E., De Tribolet N., Fontana A. Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. J Immunol 1992, 148:3140-3146.
33. Sawamura M.J., Tada Y., Sakuma S., Sudo M., Aida T., Abe H. Human glioblastoma cells produce granulocyte-macrophage colony-stimulating factor in vitro, but not in vivo without expressing its receptor. Neurol Med Chem 1993, 33:603-609.
34. Yamanaka R., Tanaka R., Saitoh T., Okoshi S. Cytokine gene expression on glioma cell lines and specimens. J Neurooncol 1994, 21:243-247.
35. Nitta T., Sato K., Allegretta M., et al. Expression of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor genes in human astrocytoma cell lines and in glioma specimens. Brain Res 1992, 571:19-25.
36. Tada M., Diserens A.C., Desbaillets I., De Tribolet N. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 1994, 80:1063-1073.
37. Mueller M.M., Herold-Mende C.C., Riede D., Lange M., Steiner H.H., Fusenig N.E. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999, 155:1557-1567.
38. Beffy P., Rovero P., Di Bartolo V., Laricchia Robbio L., Danè A., Pegoraro S., et al. An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies. Hybridoma 1994, 3:457-468.
39. Laricchia-Robbio L., Liedberg B., Platou-Vikinge T., Rovero P., Beffy P., Revoltella P.R. Mapping of monoclonal antibody- and receptor-binding domains on human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) using a surface plasmon resonance-based biosensor. Hybridoma 1996, 15:343-350.
40. Kitamura T., Tange T., Terasawa T., et al. IL-3 or erythropoietin. J Cell Physiol 1989, 140:323-334.
41. Facchinetti A., Tessarollo L., Mazzocchi M., Kingston R.T., Collavo D., Biasi G. An improved method for detection of DNA fragmentation. J Immunol Methods 1991, 136:125-131.
42. Corcione A., Corrias M.V., Daniele S., Zupo S., Spriano M., Pistoia V., et al. Blood 1996, 87:2861-2869.
43. Omerod M.G. The study of apoptotic cells by cytometry. Leukemia 1998, 12:1013-1017.
44. Gilbert E., Migeon B.R. d-Valine as a selective agent for normal human and rodent epithelial cells in culture. Cell 1975, 5:11-17.
45. Dao Ke L., Shi Y.X., Im S.A., Chen X., Yung W.K. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer. Res 2000, 6:2562-2572.
46. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
47. Cannistra S.A., Groshek P., Grlick R., Muiller J., Griffin J.D. Regulation of surface expression of the GM-CSF receptors in normal human myeloid cells. Proc Natl Acad Sci USA 1990, 87:93-97.
48. Herold-Mende C., Steiner H.H., Andl T., Riede D., Buttler D., Reisser C., et al. Lab Invest 1999, 79:1573-1582.
49. Lilly M.B., Zemskova M., Frankel A.E., Salo J., Kraft A.S. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood 2001, 97:1662-1670.
50. Sakurai Y., Ken-ichi A., Watanabe S. In vitro analysis of STAT5 activation by granulocyte-macrophage colony-stimulating factor. Genes to Cells 2000, 5:937-947.
51. Kapoor G.S., O'Rourke D.M. Receptor tyrosine kinase signalling in gliomagenesis: pathobiology and therapeutic approaches. Cancer Biol Ther 2003, 2:330-342.
52. Jensen R.L. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998, 49:1306-1309.
53. Hintzen R.Q., Voormolen J., Sonneveld P., vanDuinen S.G. Glioblastoma causing granulocytosis by secretion of granulocyte colony stimulating factor. Neurology 2000, 54:259-261.
54. Salcman M. High-grade glioma. Handbook of Clinical Neurology. Neuro-oncology 1997, 24:95-97. Amsterdam Elsevier.
55. Luminiczky K., Desaknai S., Mangel L., Szende B., Hamada H., Hidvegi E.J., et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002, 9:44-52.
56. Fenstermaker R.A., Ciesleski M.J. Immunotherapeutic strategies for malignant glioma. Cancer Control 2004, 11(3):181-191.
57. Nieder C.A., Grosu A.L., Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000, 26:397-406.
58. Wheeler C.J., Das A., Liu G., Yu J.S., Black L. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004, 10(16):5316-5326.
59. Yu J.S., Liu G., Ying H., Yong W.H., Black K.L., Wheeler C.J. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004, 64:4973-4979.
60. Rosenberg S.A., Yang J.C., Restivo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
61. Ciesielski M.J., Latif Kazim A., Berth R.F., Fanstermaker R.A. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005, 54:107-119.
62. Fine H.A. Promising new therapies for malignant gliomas. Cancer J 2007, 13:349-354.
63. Kang S.G., Jeun S.S., Lim J.Y., Kim S.M., Yang Y.S., Oh W.I., et al. Cytotoxicity of human umbilical cord-blood-derived mesenchymal stem cells against human malignant glioma cells. Childs Nerv Syst 2008, 24:293-302.
64. Mercer R.W., Tyler M.A., Ulasov I.V., Lesniak M.S. Targeted therapies for malignant gliomas: progress and potential. BioDrugs 2009, 23:25-35.
65. Okada H., Koahanbash G., Zhu X., et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009, 29:1-42.
66. Vauleon E., Avril T., Collet B., Mosser J., Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010, 18. (Article ID 689171).
67. Herrlinger U., Kramm C.M., Johnston K.M., Louis D.N., Finkelstein D., Reznikoff G., et al. Vaccination for experimental gliomas using GM-CSF - Transduced glioma cells. Cancer Gene Ther 1997, 4(6):345-352.
68. Herrlinger U., Aulwurm S., Strik H., Weit S., Naumann U., Weller M. MIP-1 antagonizes the effect of GM-CSF-enhanced subcoutaneous vaccine in a mouse glioma model. J Neuro Oncol 2004, 66:147-154.
69. Jean W.C., Spellman S.R., Wallenfriendman M.A., et al. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J Neuro Oncol 2004, 66:39-49.
70. Tseng S.H., Chen Y., Chang C.Y., et al. Clin Cancer Res 2005, 11:1639-1649.
71. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18(2):226-232.
72. Smith K.E., Fritzell S., Badn W., Ebastal S., Janelidre S., Visse E. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNγ is mediated by both CD8+ and CD4+ cells. Int J Cancer 2009, 124:630-637.
73. Clavreul A., Piard N., Tanguy S.Y., Gamlin E., Rouselet M.C., Leynia P., et al. Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant glioma. J Clin Neurosci 2010, 17:842-848.